PubMed Health⌕ Search

Biomedical subjects

A Fujimura

Publications and source records attributed to A Fujimura.

At least 235 records · Page 13Linked to original sources
PubMed1989

[Morphological studies on the margo infraorbitalis (on the longitudinal changes of infraorbital suture)].

The purpose of this study was to obtain information on the developmental changes of the infraorbital margin and the form of infraorbital suture. 136 Indian craniums were divided into five developmental groups according to the stage of eruption of the teeth. The anterior view of the skull was observed photographically. The results are summarized as follows: 1. The infraorbital margins were divided into three types according to the shape of the infraorbital suture. Type I: Infraorbital suture was independent. Type II: Infraorbital suture and zygomatico-facial suture coincided. Type III: Infraorbital suture and zygomatico-facial suture were joined. Type I was the basic type of infraorbital suture. 2. The frequency of type I was 90% at the pre-eruption stage, 31.8% at the eruption stage, 41.7% at the deciduous dentition stage, 56.3% at the mixed dentition stage, and 62% at the permanent dentition stage. 3. On the distance between the median line and each point of the infraorbital margin the growth rate is expressed in values relative to a standard that was based on the pre-eruption stage. The growth rate was greatest at the highest point of the superior margin in the infraorbital foramen (1.79 times), the middle rate was at the position of the infraorbital suture (1.72 times) and the smallest rate was 1.63 times at the position of the zygomatico-facial suture. Each measuring point moved towards lateral side.

Cephalometry↗
PubMed1989

Chronopharmacological study of bunazosin hydrochloride in healthy subjects.

Bunazosin, an alpha-1 adrenoreceptor blocking agent, was given orally to six healthy subjects in the morning or in the evening in order to examine the time-dependent variations in the pharmacological effects of the drug. The study was carried out on four occasions in a placebo controlled cross-over design. No significant change was observed in blood pressure either after the morning or the evening dosage. Finger skin blood flow (FSBF) assessed by laser Doppler flowmetry increased significantly after the morning dosage, but not after the evening trial. The plasma concentration of bunazosin in the morning in general had a tendency to be greater than that in the evening. A significant correlation was observed between the plasma concentrations and the increments in the FSBF. These results indicate that the pharmacological effects of bunazosin are greater following morning dosage. The present study supports the concept that the time-dependent differences in the effect of bunazosin are, at least, caused by the time-dependent changes in plasma drug concentration.

Adrenergic alpha-Antagonists↗
PubMed1989

[Longitudinal changes in amounts of maxillary growth].

The purpose of this study is to investigate postnatal developmental changes in the shape of the maxilla. Normal maxillary form at each development stage and amounts of growth were analyzed by longitudinally measuring 136 Indian skulls. Maxillary growth changes were assumed on the basis of mean values and growth rates of each region measured. Results 1) Vertical growth Vertical growth of the maxilla (N-Pr) at the fifth (permanent-dentition) stage approximately doubled growth in the first (pre-eruption) stage. The corpus of the maxilla and its alveolar process lay beneath the foramen infraorbit. Vertical growth in this region (m-Pr) increases rapidly during the period of eruption of deciduous and permanent teeth. In permanent dentition, the vertical dimensions of the upper (N-m) and lower (m-Pr) parts of the foramen infraorbit were almost the same. 2) Growth in width As the eyes grow, the upper face widens. Resulting development in the tensed zygomatic-maxillary suture at the inferior margin of the orbit expands the upper surface of maxilla. Maxillary width increased by approximately 1.8 times between the first and fifth stages.

Cephalometry↗
PubMed1988

Chronopharmacological study of furosemide in rats: (II). Influence of beta-adrenoceptor blockade.

We have previously demonstrated a time-dependent variability in the diuretic effect of furosemide in rats. The present study was undertaken to evaluate the influence of beta-adrenoceptor blockade on these time-dependent variations. Furosemide (5 mg/kg) was administered intra-arterially in Wistar rats at 1000 hrs (03HALO) or at 2200 hrs (15HALO) with pretreatment with either propranolol (10 mg/kg) or atenolol (10 mg/kg). Urine was collected for 60 min after furosemide administration and urinary excretion of sodium and furosemide were determined respectively. Propranolol pretreatment abolished the temporal variations observed in urine volume, urinary sodium and furosemide levels during the observation periods. With atenolol pretreatment, however, all these variables were significantly greater at 1000 hrs (03HALO) than at 2200 hrs (15HALO) as observed in the previous study. These results suggest that the beta-adrenoceptor-mediated stimuli, which is blocked by propranolol but not by atenolol, is responsible for the time-dependent changes in the diuretic effect of furosemide.

Animals↗
PubMed1988

Role of angiotensin II in renal prostaglandin E2 production after furosemide administration.

The role of plasma angiotensin II (Ang II) in furosemide-stimulated renal prostaglandin E2 (PGE2) production was evaluated in eight healthy subjects. Urine was collected for 60 minutes after furosemide administration (20 mg i.v.) with or without captopril pretreatment, and urinary excretion of PGE2, sodium, and furosemide was determined. Plasma renin activity (PRA) and Ang II were also measured before and 60 minutes after furosemide administration. Urinary PGE2 excretion, PRA, and Ang II increased after furosemide administration without captopril pretreatment, and there was a significant correlation between the increment in Ang II and that in urinary PGE2 excretion. Urinary PGE2 excretion and Ang II did not increase after furosemide administration with captopril pretreatment. Urine volume and urinary excretion of sodium and furosemide were not influenced by captopril pretreatment. These results suggest that Ang II may play an important role in furosemide-stimulated PGE2 production.

Adult↗
PubMed1988

Chronopharmacological study of furosemide in human subjects.

The present study was undertaken to determine whether the diuretic effects of furosemide depend on the administration time or not. After furosemide 20 mg or a placebo was administered intravenously in 12 human subjects at 09h00 or at 21h00, urine volume and urinary excretion of sodium, chloride and furosemide were determined for 3 h. There were no significant differences in the amount of urine, or of urinary excretion of sodium and chloride between when a placebo was given at 09h00 and when it was given at 21h00. When furosemide was administered at 21h00, the urine volume and urinary excretion of sodium, chloride and furosemide during the first 60 min were significantly greater than those, when the drug was administered at 09h00. There was a marked correlation between the urinary output of furosmeide and the urine volume, urinary sodium and urinary chloride. These results suggest that the diuretic effects of furosemide vary with the time of administration and the observed variations are mainly dependent on the amount of furosemide secreted into urine.

Adult↗
PubMed1987

The effect of propranolol on urinary prostaglandin E2 after frusemide administration in healthy subjects.

We have evaluated the effect of propranolol on urinary prostaglandin E2 (PGE2) excretion after frusemide administration in 8 healthy subjects. Urine was collected for 60 min after frusemide administration (20 mg intravenously) with or without propranolol pretreatment, and urinary excretion of PGE2, frusemide, and sodium were determined. Plasma renin activity (PRA) was also measured before and 60 min after frusemide administration. Urinary PGE2 excretion after frusemide administration and frusemide-stimulated PRA were reduced after propranolol pretreatment. However, urine volume and the urinary excretion of frusemide and sodium were not influenced by propranolol pretreatment. These results suggest that urinary PGE2 excretion after frusemide administration may be reduced by propranolol and that the mechanism responsible for the effect of propranolol on the frusemide-induced renal PGE2 production may be, at least in part, secondary to inhibition of the renin-angiotensin system.

Adult↗
PubMed1987

Chronotoxicity of beta-adrenoceptor blocking agent in spontaneously hypertensive rats.

1. Chronotoxicity of a single LD50 dosage of beta-adrenoceptor blocking agent, pindolol, was determined in spontaneously hypertensive rats (SHR) and Wistar-Kyoto control rats (WKY). 2. The 24 h mortality was greater when pindolol was administered at 00.00 h than when it was administered at 12.00 h in both SHR and WKY. 3. The chronogram of the mortality in SHR was similar to that in WKY. 4. These results indicate that the mode of circadian variation in the acute toxicity of pindolol in SHR is not different from that in WKY.

Adrenergic beta-Antagonists↗
PubMed1987

Diuretic and uricosuric effects of traxanox sodium in healthy subjects. Single dose study.

A new compound, 9-chloro-5-oxo-7-(1H-tetrazol-5-yl)-5H-[1]-benzopyrano[2,3- b]pyridine sodium salt pentahydrate (traxanox sodium, Y-12141) has been shown to exert uricosuric effect in animal experiments. This study was performed to investigate the pharmacokinetics and pharmacological effects of this compound in healthy subjects by double-blind, cross-over comparison with placebo. The urine volume and urinary electrolytes increased significantly after single oral doses of 120 and 360 mg. Urinary excretion of uric acid tended to increase and serum uric acid decreased significantly. Traxanox sodium did not induce any significant change in blood pressure and pulse rate. These results suggest that traxanox sodium is a useful diuretic agent with uricosuric effect.

Administration, Oral↗